Multitude Therapeutics out-licensed global rights (ex-Greater China) for its Tissue Factor ADC to Denmark’s Adcendo in a $1 billion agreement. Huadong Pharmaceutical acquired rights for two immune ...
Data published online in the journal Cytotherapy demonstrate that CRISPR-mediated tissue factor gene knockout (TFKO) in allogeneic stromal cells (ASCs) leads to significantly lower tissue factor (TF) ...
The expression of tissue factor (TF) is limited in normal tissues to the perivascular compartment where it acts as the receptor for the serin protease factor VIIa. This signaling axis triggers the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback